Bayer, a leading global life sciences company, is charting a new course for its Pharmaceutical Division with a strategic overhaul of its executive leadership team, aiming to enhance its mission-centric and value-focused approach. This reorganization is part of Bayer’s ongoing efforts to bolster its development portfolio, particularly in pioneering therapeutic fields such as gene and cell therapies, and to solidify its position as a pivotal growth driver within the broader Bayer conglomerate.
Starting April 1, 2024, Sebastian Guth will step into the role of Chief Operating Officer (COO) for Bayer’s Pharmaceutical Division. Guth’s primary focus will be overseeing the commercial operations across all active markets, driving the commercial strategy to bolster customer value, tap into market opportunities, and elevate revenue growth and profitability on a global scale. Guth, who will continue to report to Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceutical Division, will also maintain his base in the U.S. to support the company’s strategic objectives, particularly its expansion in the U.S market.
Christine Roth, currently at the helm of Bayer’s strategic business unit Oncology, will lead the newly established “Global Commercialization” organization starting June 1, 2024. This entity merges significant components of the company’s former Oncology unit, Global Marketing, Digital & Commercial Innovation, and sections of Medical Affairs & Pharmacovigilance, reflecting Bayer’s shift towards a more integrated and collaborative operational framework.
Get Your Organization Happy Place To Work (HPTW) Certified : Why Workplace Happiness Matters Now More Than Ever
HAPPY PLACE TO WORK INSTITUTE (www.happyplacetowork.org)
Christian Rommel will continue to oversee “Research & Development,” and Holger Weintritt will maintain leadership over “Product Supply,” with both reporting to Stefan Oelrich. This leadership continuity ensures that Bayer’s Pharmaceutical Division remains at the forefront of innovation and supply chain excellence.
Stefan Oelrich highlighted the transformative nature of this leadership shift, stating, “We have decided to dismantle our traditional model with functional silos and many layers of hierarchy. We are replacing it with our new operating model, which has Product and Customer Teams at its center.” This strategic realignment underscores Bayer’s commitment to realizing the full potential of its growth opportunities through a more agile and customer-focused operational model.
